PTC Reports Positive Phase II Huntington’s Data, FDA Lifts Partial Clinical Hold

PTC Reports Positive Phase II Huntington’s Data, FDA Lifts Partial Clinical Hold

Source: 
BioSpace
snippet: 

PTC Therapeutics announced Thursday that its Huntington’s disease candidate PTC518 is no longer subject to an FDA partial clinical hold after it showed positive interim results from a Phase II study.